Latest Estrogen Stories
Breast cancer is the most prevalent cancer among women and affects approximately one million women worldwide. But a new study shows many postmenopausal women who are treated for estrogen-sensitive breast cancer quit using drugs that help prevent the disease from recurring because of side effects.
Why do so many postmenopausal women who are treated for estrogen-sensitive breast cancer quit using drugs that help prevent the disease from recurring?
A strong risk factor for cancer in women is childlessness, and a new study in The Lancet suggests that nuns be prescribed the contraceptive pill in hopes of reducing enhanced death rates of nuns from breast, ovarian and uterine cancer that result from their childlessness.
Changing the order in which two drugs are taken significantly extended the lives of women with metastatic breast cancer, a study has found.
Researchers have proven the continuing effectiveness of treating patients with estrogen receptor-positive premenopausal breast cancer with adjuvant zoledronic acid in addition to adjuvant endocrine treatment including ovarian function suppression.
The Food and Drug Administration said on Tuesday that they are leaning towards adding new information about the risk of blood clots to labels of birth control pills.
An international team of researchers has reviewed the evidence linking exposure to atrazine – an herbicide widely used in the U.S. and more than 60 other nations – to reproductive problems in animals.
About half of male breast cancer patients who take the drug tamoxifen to prevent their disease from returning report side effects such as weight gain and sexual dysfunction, which prompts more than 20 percent of them to discontinue treatment.
Research suggests that use of the contraceptive pill is associated with an increased risk of prostate cancer, which is the most common cancer type among males in the developed world.
- a meat pie that is usually eaten at Christmas in Quebec
More Images (1 images) »